Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Breast Cancer

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

Supply readiness plus high rates of severe mouth inflammation create uncertainty over patient use and commercial uptake.

Anvisa Approves Inluriyo as Oral Treatment for ER‑Positive, HER2‑Negative, ESR1‑Mutant Advanced Breast Cancer

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

FDA Expands Approval of Kisqali for Early-Stage Breast Cancer